<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02881190</url>
  </required_header>
  <id_info>
    <org_study_id>C002 CANCER</org_study_id>
    <nct_id>NCT02881190</nct_id>
  </id_info>
  <brief_title>Study of RC48-ADC Administered Intravenously to Subjects With HER2-Positive in Advanced Malignant Solid Tumors</brief_title>
  <official_title>A Tolerance, Safety and Pharmacokinetic Ascending Dose Phase I Study of RC48-ADC Administered Intravenously to Subjects With HER2-Positive Malignant in Advanced Malignant Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RemeGen Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RemeGen Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A tolerance, safety and pharmacokinetic ascending dose phase I Study of RC48-ADC administered&#xD;
      intravenously to subjects with HER2-positive malignant in advanced malignant solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 14, 2015</start_date>
  <completion_date type="Actual">November 8, 2019</completion_date>
  <primary_completion_date type="Actual">June 27, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal Tolerance Dose (MTD) of RC48-ADC</measure>
    <time_frame>DLT will be evaluated on Day 28 during cycle 1</time_frame>
    <description>The dose level in which &gt;= 2 out of 6 patients have dose-limiting toxicity (DLT). The MTD is defined as the previous dose level.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety (the drug safety as assessed by NCI-CTCAE v4.0)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>The drug safety as assessed by NCI-CTCAE v4.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>RC48-ADC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The phase I component has several dose levels of RC48-ADC (0.1mg/kg，0.5 mg/kg, 1.0mg/kg, 1.5mg/kg, 2.0mg/kg, 2.5mg/kg, 3.0mg/kg, 3.5mg/kg and 4.0 mg/kg) and is designed as a traditional dose-escalation study.Dosing interval is once two weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RC48-ADC</intervention_name>
    <arm_group_label>RC48-ADC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent form;&#xD;
&#xD;
          -  Aged 18-75 years;&#xD;
&#xD;
          -  ECOG physical condition is 0 or 1;&#xD;
&#xD;
          -  Life expectancy greater than 12 weeks;&#xD;
&#xD;
          -  Patients with locally advanced or metastatic malignant solid tumors diagnosed by&#xD;
             pathology and refractory to standard of care therapy, or for whom no standard of care&#xD;
             therapy is available histology standard of care therapy, or for whom no standard of&#xD;
             care therapy is available;&#xD;
&#xD;
          -  Human epidermal growth factor receptor 2 (HER2)-positive refers to&#xD;
             immunohistochemistry (IHC 2+or 3+);&#xD;
&#xD;
          -  Patients with measurable and appreciable tumor lesions according to Response&#xD;
             Evaluation Criteria in Solid Tumors (RECIST 1.1);&#xD;
&#xD;
          -  Adequate organ function as defined by the following criteria:&#xD;
&#xD;
               -  absolute neutrophil count(ANC) &gt;= 1.5 x 10(9)/L;&#xD;
&#xD;
               -  platelets&gt;=100*10(9)/L;&#xD;
&#xD;
               -  Total serum bilirubin &lt;=1.5*ULN;&#xD;
&#xD;
               -  serum aspartate transaminase (AST) and serum alanine transaminase (ALT)&#xD;
                  &lt;=3.0*upper limit of normal (ULN), or AST and ALT&lt;=5*ULN if liver function&#xD;
                  abnormalities are due to underlying malignancy;&#xD;
&#xD;
               -  normal serum creatinine;&#xD;
&#xD;
               -  international normalized ratio(INR) and activated partial thromboplastin time&#xD;
                  (aPTT) must be less than or equal to 1.5 times the upper limit of the normal&#xD;
                  range (ULN);&#xD;
&#xD;
          -  Women of child-bearing potential and men must agree to use adequate contraception&#xD;
             (e.g., condoms, implants, injectables, combined oral contraceptives, some intrauterine&#xD;
             devices [IUDs], complete sexual abstinence, or sterilized partner) prior to study&#xD;
             entry and during the period of therapy and for 30 days after the last dose of study&#xD;
             drug;&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) &gt;= 50% as assessed by echocardiogram.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current pregnancy or lactation;&#xD;
&#xD;
          -  Serologic status reflecting active hepatitis B or C infection;&#xD;
&#xD;
          -  Major surgery within 4 weeks of first dose of study drug and not fully recovered&#xD;
&#xD;
          -  Receiving palliative radiation therapy for bone metastases if administered &lt;= 2 weeks&#xD;
             prior to first study treatment;&#xD;
&#xD;
          -  Unresolved toxicities from prior anti-cancer therapy, defined as having not resolved&#xD;
             to Common Terminology Criteria for Adverse Event (CTCAE, version 4), grade less than&#xD;
             or equal to1, or to the levels dictated in the inclusion/exclusion criteria with the&#xD;
             exception of alopecia;&#xD;
&#xD;
          -  Prior-treatment with other clinical research anticancer drugs within 28 days before&#xD;
             study drug treatment;&#xD;
&#xD;
          -  The active infection with clinical significance According to the researcher's&#xD;
             judgment,&#xD;
&#xD;
          -  Known history of immune deficiency,including HIV-positive or other known acquired or&#xD;
             congenital immunodeficiency, or organ transplantation;&#xD;
&#xD;
          -  Currently active clinically significant cardiovascular disease such as uncontrolled&#xD;
             arrhythmia, congestive heart failure, or greater than or equal to Class 2 congestive&#xD;
             heart failure as defined by the New York Heart Association Functional Classification,&#xD;
             or history of myocardial infarction unstable angina, or acute coronary syndrome within&#xD;
             6 months prior to enrollment in the study;&#xD;
&#xD;
          -  Unwilling or unable to participate in all required study evaluations and procedures;&#xD;
&#xD;
          -  The time interval which is from the last chemotherapy or HER2 targeted therapy until&#xD;
             the first trial is more than 21 days;&#xD;
&#xD;
          -  Patients who had received systemic steroid therapy for a long time (Patients who had&#xD;
             received systemic steroid therapy for short time and stopped drug more than 2 weeks&#xD;
             could be enrolled);&#xD;
&#xD;
          -  Serious complications such as active alimentary tract hemorrhage, intestinal&#xD;
             obstruction, enteroparalysis, interstitial pneumonia, pulmonary fibrosis, renal&#xD;
             failure, glaucoma and uncontrolled diabetes;&#xD;
&#xD;
          -  Uncontrolled primary or metastatic tumor of brain;&#xD;
&#xD;
          -  Current peripheral neuropathy of Grade ≥ 2;&#xD;
&#xD;
          -  History of nerve or psychiatric disorders.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lin Shen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>August 20, 2016</study_first_submitted>
  <study_first_submitted_qc>August 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2016</study_first_posted>
  <last_update_submitted>June 2, 2020</last_update_submitted>
  <last_update_submitted_qc>June 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

